![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Bibliography
- Von Behring E, Kitasato S. Uber das zustandekommen der diphterieimmunitaet und der tetanus-immunitant bei thieren. Dtsch Med Wochenschr 1890;16:1113-4
- Good RA, Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer 1991;68:1415-21
- Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995;273:1865-70
- Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741-53
- Weeks JS, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6
- Cordonnier C, Chevret S, Legarand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003;139:8-18
- Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immuneodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994;331:1181-7
- Intravenous Immuno Globulin. Available from: http://www.blooddiagnostics.com/Comparison%20Charts/IVIG_Chart.pdf [Last accessed 2/6/08]
- IvIg therapies. Available from: http://www.medprorx.com/forms/MedProRx_IVIg_chart.pdf [Last accessed 2/6/08]
- Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592-9
- Baxter Healthcare Corporation. Gammagard liquid (Immune Globulin Intravenous (Human) 10%) package insert. Westlake Village, CA; April 2005
- Bjorkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 2006;90:286-93
- Poelsler G, Berting A, Kindermann J, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps. Virus and prion reduction capacity. Vox Sang 2008;94(3):184-92
- Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol 2006;26:388-95
- Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003;84:202-10
- Berger M, Pinciaro PJ; Flebogamma® 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma(R) 5% (immune globulin intravenous (human)) for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004;24:389-96
- Varga G, Volkova Z, Leibl H, et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006;33:509-14
- Renal insufficiency and failure associated with immune globulin intravenous therapy – United States, 1985 – 1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21
- Sati HI, Ahya R, Watson HG. Incidence and associations of acuter renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001;113:556-7
- Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm 2005;62:720-5
- Ochs HD, Pinciaro PJ; The Octagam Study Group. Octagam® 5%, an intravenous IgG product, is efficacious and well tolerate in subjects with primary immunodeficiency diseases. J Clin Immunol 2004;24:309-14
- Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265-73
- CSL Behring LLC. Privigen™ (Immune Globulin Intravenous (Human) 10% liquid) package insert. Kankakee, IL 60901; July 2007
- Berger M, Cunningham-Rundles C, Bonilla FA, et al. Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immujodeficiency diseases. J Clin Immunol 2007;27:503-9
- Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency – a randomized double-blind trial. Int Immunopharmacol 2003;3:1325-33
- Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53
- Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23-9
- Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104(Suppl 1):35-42
- Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996;276:1563-7
- Healey CJ, Sabharwal NK, Daub J, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy. Gastroenterology 1996;100:1120-6
- Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1994;43:505-9
- Berger A, Doerr HW, Scharrer I, Weber B. Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission. J Med Virol 1997;53:25-30
- Yap LP. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data. Clin Ther 1996;18(Suppl B):43-58
- Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003;17:241-51
- McCue JP, Hein RH, Tenold R. Three generation of immunoglobulin G prepartions for clinical use. Rev Infect Dis 1986;8(Suppl 4):S374-81
- Talecris Biotherapeutics, Inc. Gamunex® (Immune Globulin Intravenous (Human), 10% caprylate/chromatography purified) package insert. Research triangle park, NC; November 2005